Second immunotherapy, completed it mate.
Now to restart in 6 months time
Now to restart in 6 months time
November 2, 2026 at 5:08 PM
Second immunotherapy, completed it mate.
Now to restart in 6 months time
Now to restart in 6 months time
My sister's tumor has shrunk, vertically, from 54mm to 35mm!
That's after 3 immunotherapy treatments.
That's after 3 immunotherapy treatments.
October 30, 2026 at 8:58 AM
My sister's tumor has shrunk, vertically, from 54mm to 35mm!
That's after 3 immunotherapy treatments.
That's after 3 immunotherapy treatments.
A personalized cancer vaccine from Moderna called Intismeran (also known as mRNA-1457) used in combination with Merck’s cancer immunotherapy Keytruda shows promise in keeping deadly skin cancer from returning for years, according to new clinical trial results. The mRNA-based vaccine was tested
November 2, 2026 at 5:02 PM
A personalized cancer vaccine from Moderna called Intismeran (also known as mRNA-1457) used in combination with Merck’s cancer immunotherapy Keytruda shows promise in keeping deadly skin cancer from returning for years, according to new clinical trial results. The mRNA-based vaccine was tested
My first immunotherapy visit, in the company of Becky Chambers’ The Long Way to a Small Angry Planet. Science-fictional reading during a treatment that would have been science fiction ten years ago.
November 2, 2026 at 5:17 PM
My first immunotherapy visit, in the company of Becky Chambers’ The Long Way to a Small Angry Planet. Science-fictional reading during a treatment that would have been science fiction ten years ago.
Sonosensitizer-Functionalized Polymetallic Nanoenzymes for Photoacoustic Imaging-Guided Cancer Sonodynamic Immunotherapy
Sonosensitizer-Functionalized Polymetallic Nanoenzymes for Photoacoustic Imaging-Guided Cancer Sonodynamic Immunotherapy
doi.org/10.1002/smm2...
doi.org/10.1002/smm2...
November 2, 2026 at 3:27 PM
Sonosensitizer-Functionalized Polymetallic Nanoenzymes for Photoacoustic Imaging-Guided Cancer Sonodynamic Immunotherapy
Sonosensitizer-Functionalized Polymetallic Nanoenzymes for Photoacoustic Imaging-Guided Cancer Sonodynamic Immunotherapy
Sonosensitizer-Functionalized Polymetallic Nanoenzymes for Photoacoustic Imaging-Guided Cancer Sonodynamic Immunotherapy
doi.org/10.1002/smm2...
doi.org/10.1002/smm2...
November 2, 2026 at 3:23 PM
Sonosensitizer-Functionalized Polymetallic Nanoenzymes for Photoacoustic Imaging-Guided Cancer Sonodynamic Immunotherapy
what immunotherapy did you do
October 30, 2026 at 3:29 AM
what immunotherapy did you do
Sonosensitizer-Functionalized Polymetallic Nanoenzymes for Photoacoustic Imaging-Guided Cancer Sonodynamic Immunotherapy
doi.org/10.1002/smm2...
doi.org/10.1002/smm2...
November 2, 2026 at 12:29 PM
Sonosensitizer-Functionalized Polymetallic Nanoenzymes for Photoacoustic Imaging-Guided Cancer Sonodynamic Immunotherapy
doi.org/10.1002/smm2...
doi.org/10.1002/smm2...
about three weeks apart. The doses aligned with their immunotherapy treatments.
In other words, Merck and Moderna’s personalized vaccine is designed to target the specific mutations in each patient’s tumor rather than using a one-size-fits-all approach.
In other words, Merck and Moderna’s personalized vaccine is designed to target the specific mutations in each patient’s tumor rather than using a one-size-fits-all approach.
November 2, 2026 at 5:10 PM
about three weeks apart. The doses aligned with their immunotherapy treatments.
In other words, Merck and Moderna’s personalized vaccine is designed to target the specific mutations in each patient’s tumor rather than using a one-size-fits-all approach.
In other words, Merck and Moderna’s personalized vaccine is designed to target the specific mutations in each patient’s tumor rather than using a one-size-fits-all approach.
Researchers said the results of the large-scale, Phase III trial, which included over 1,000 patients and expanded to Europe, has provided the real proof that personalized mRNA vaccines added to standard immunotherapy significantly reduce the risk of melanoma returning.
November 2, 2026 at 5:12 PM
Researchers said the results of the large-scale, Phase III trial, which included over 1,000 patients and expanded to Europe, has provided the real proof that personalized mRNA vaccines added to standard immunotherapy significantly reduce the risk of melanoma returning.
This is Oliver, my mom's weird cat.
We can now be friends thanks to my year+ of immunotherapy.
We can now be friends thanks to my year+ of immunotherapy.
October 30, 2026 at 3:27 AM
This is Oliver, my mom's weird cat.
We can now be friends thanks to my year+ of immunotherapy.
We can now be friends thanks to my year+ of immunotherapy.
Your last-minute guide to Proposition 38: Research funding for immunology, immunotherapy
Your last-minute guide to Proposition 38: Research funding for immunology, immunotherapy
Proposition 38 asks voters to approve $8.4 billion in funding for immunology and immunotherapy research that aims to cure and prevent cancer, heart disease and Alzheimer’s disease.
www.latimes.com
October 31, 2026 at 9:08 AM
Your last-minute guide to Proposition 38: Research funding for immunology, immunotherapy
Cluster immunotherapy for cats/grasses/flowers/some trees
October 30, 2026 at 3:37 AM
Cluster immunotherapy for cats/grasses/flowers/some trees
Your last-minute guide to Proposition 38: Research funding for immunology, immunotherapy
Your last-minute guide to Proposition 38: Research funding for immunology, immunotherapy
Proposition 38 asks voters to approve $8.4 billion in funding for immunology and immunotherapy research that aims to cure and prevent cancer, heart disease and Alzheimer’s disease.
www.latimes.com
October 30, 2026 at 7:57 PM
Your last-minute guide to Proposition 38: Research funding for immunology, immunotherapy
Immorta Bio Pioneers First Human Trial of SenoMune™-0257 Immunotherapy Targeting Cellular Aging#None#Mexico#Immunotherapy#Immorta_Bio#Senomune
Immorta Bio Pioneers First Human Trial of SenoMune™-0257 Immunotherapy Targeting Cellular Aging
Immorta Bio's recent advancement marks a groundbreaking step in aging research with the first human administration of SenoMune™-0257, targeting age-related diseases.
third-news.com
November 2, 2026 at 1:56 PM
Immorta Bio Pioneers First Human Trial of SenoMune™-0257 Immunotherapy Targeting Cellular Aging#None#Mexico#Immunotherapy#Immorta_Bio#Senomune
A North Carolina man enrolled in an early-stage trial that combined a new type of immunotherapy drug with the current first-line treatment for small-cell lung cancer. More than two years after his diagnosis, there are no detectable signs of cancer in his body.
New immunotherapy combination helps people with small-cell lung cancer live longer
People with small-cell lung cancer could live significantly longer on a novel immunotherapy, even when their cancer has spread, Phase 3 trial results show.
nbcnews.to
October 27, 2026 at 2:00 AM
A North Carolina man enrolled in an early-stage trial that combined a new type of immunotherapy drug with the current first-line treatment for small-cell lung cancer. More than two years after his diagnosis, there are no detectable signs of cancer in his body.
i've been talking about getting immunotherapy since september and one of my "i'm praying for you" ass family members says "hey you should talk to your oncologist about immunotherapy"
bxtch if you don't--
bxtch if you don't--
October 29, 2026 at 4:20 PM
i've been talking about getting immunotherapy since september and one of my "i'm praying for you" ass family members says "hey you should talk to your oncologist about immunotherapy"
bxtch if you don't--
bxtch if you don't--
Charles Couturier wins Marathon of Hope Clinician-Scientist Award ⭐ Congrats to The Neuro investigator, who was recognized for his work identifying new immune-targeting treatment strategies to ultimately help brain tumours respond better to immunotherapy. 🔗https://ow.ly/KrTl5100guA
November 2, 2026 at 2:00 PM
Charles Couturier wins Marathon of Hope Clinician-Scientist Award ⭐ Congrats to The Neuro investigator, who was recognized for his work identifying new immune-targeting treatment strategies to ultimately help brain tumours respond better to immunotherapy. 🔗https://ow.ly/KrTl5100guA
Checkpoint immunotherapy reorganized immune cells in melanoma-affected lymph nodes in a preclinical model, moving macrophages and T cells farther apart. Whether this occurs in patients remains unknown. doi.org/hcqtjr
Checkpoint immunotherapy reshapes immune environment in lymph nodes after melanoma reaches them
A new study from Mayo Clinic suggests checkpoint immunotherapy may reshape the immune environment within lymph nodes after melanoma has spread to them.
medicalxpress.com
October 30, 2026 at 5:20 PM
Checkpoint immunotherapy reorganized immune cells in melanoma-affected lymph nodes in a preclinical model, moving macrophages and T cells farther apart. Whether this occurs in patients remains unknown. doi.org/hcqtjr
#Radiotherapy can also attract immune cells that help #tumors resist treatment. This review explains how CCL2/CCR2 signaling recruits these cells and explores whether blocking this pathway could improve combinations of radiation and #immunotherapy.👇
link.springer.com/article/10.1...
link.springer.com/article/10.1...
November 2, 2026 at 5:07 AM
#Radiotherapy can also attract immune cells that help #tumors resist treatment. This review explains how CCL2/CCR2 signaling recruits these cells and explores whether blocking this pathway could improve combinations of radiation and #immunotherapy.👇
link.springer.com/article/10.1...
link.springer.com/article/10.1...
Another mRNA win!💉🧬
“A personalized cancer vaccine from Moderna called Intismeran (also known as mRNA-1457) used in combination with Merck’s cancer immunotherapy Keytruda shows promise in keeping deadly skin cancer from returning for years, according to new clinical trial results.”
🧵
“A personalized cancer vaccine from Moderna called Intismeran (also known as mRNA-1457) used in combination with Merck’s cancer immunotherapy Keytruda shows promise in keeping deadly skin cancer from returning for years, according to new clinical trial results.”
🧵
GOOD NEWS! A personalized mRNA vaccine, known as mRNA-1457, has SUCCEEDED in keeping melanoma, a deadly skin cancer, from returning. Phase III clinical trial results in MORE THAN 1,100 patients shows the vaccine SIGNIFICANTLY cut the risk of death OR recurrence of melanoma by ALMOST HALF.
Breakthrough vaccine for the deadliest skin cancer cut risk by almost half
The skin cancer vaccine is based on mRNA technology that helped end the coronavirus pandemic.
www.washingtonpost.com
November 2, 2026 at 5:13 PM
Another mRNA win!💉🧬
“A personalized cancer vaccine from Moderna called Intismeran (also known as mRNA-1457) used in combination with Merck’s cancer immunotherapy Keytruda shows promise in keeping deadly skin cancer from returning for years, according to new clinical trial results.”
🧵
“A personalized cancer vaccine from Moderna called Intismeran (also known as mRNA-1457) used in combination with Merck’s cancer immunotherapy Keytruda shows promise in keeping deadly skin cancer from returning for years, according to new clinical trial results.”
🧵
that AND I finally started to feel human again after immunotherapy 2 weeks ago. 2nd one of Monday though booo
October 31, 2026 at 12:03 AM
that AND I finally started to feel human again after immunotherapy 2 weeks ago. 2nd one of Monday though booo
A personalized mRNA vaccine has reduced the risk of skin cancer returning or the recipient dying by 42% when used alongside the immunotherapy pembrolizumab.
Guardian
Guardian
October 29, 2026 at 4:44 PM
A personalized mRNA vaccine has reduced the risk of skin cancer returning or the recipient dying by 42% when used alongside the immunotherapy pembrolizumab.
Guardian
Guardian
We have an mRNA vaccine for melanoma!
Merck's melanoma vaccine trial shows reduced recurrence or death from skin cancer
Merck presented its mRNA melanoma vaccine trial data at a European cancer conference this weekend. Results are promising: The vaccine reduces recurrence and death alongside an immunotherapy drug.
www.npr.org
November 2, 2026 at 9:24 PM
We have an mRNA vaccine for melanoma!